Skip to main navigation

Home
About
Science
Clinical Studies
Investor Relations
Media
- CG in the News
- Media Resources
Careers
Contact

Press Releases

Year

Dec 16, 2024

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Dec 12, 2024

CG Oncology Announces Pricing of Public Offering

Dec 11, 2024

CG Oncology Announces Proposed Public Offering

Dec 06, 2024

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 05, 2024

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Dec 02, 2024

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

Nov 20, 2024

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

Nov 12, 2024

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 11, 2024

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

Aug 30, 2024

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22

CG ONCOLOGY, INC.
400 Spectrum Center Drive
Suite 2040
Irvine, CA 92618

Twitter opens in new window
LinkedIn opens in new window

GENERAL INQUIRIES

information@cgoncology.com

MEDICAL AFFAIRS

medicalaffairs@cgoncology.com

MEDIA

mediarelations@cgoncology.com

PARTNERS

bd@cgoncology.com

INVESTORS

ir@cgoncology.com

Privacy Policy
Terms of Service

Copyright All Rights Reserved CG Oncology | © 2024

US-UNBR-1007-v1 03/2024

Search Investors

Search this site